Digene licenses cervical cancer marker:
This article was originally published in Clinica
Molecular diagnostics company Digene has obtained worldwide rights to a genetic marker linked to cervical cancer. The p53arg gene, which the Beltsville, Maryland-based company licensed from McGill University in Montreal, Canada and the International Centre for Genetic Engineering and Biotechnology in Trieste, Italy, has been shown to predict cancers related to the human papillomavirus (HPV), of which cervical cancer is one. Digene's lead product is a DNA test for the HPV virus and is used as an adjunct to Pap smear testing in the US. A test for the p53arg gene could make HPV testing more effective for earlier cancer prognosis, said Digene.